Literature DB >> 12942569

The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with nonsmall cell lung carcinoma.

Yuka Fujita1, Toshiaki Fujikane, Satoru Fujiuchi, Yutaka Nishigaki, Yasuhiro Yamazaki, Atsushi Nagase, Tetsuo Shimizu, Yoshinobu Ohsaki, Kenjiro Kikuchi.   

Abstract

BACKGROUND: The objectives of this study were to evaluate the diagnostic and prognostic relevance of human telomerase reverse transcriptase (hTERT) detected in situ in patients with nonsmall cell lung carcinoma (NSCLC) and to investigate the possible correlations between hTERT mRNA in NSCLC and the patients' clinicopathologic features, including survival.
METHODS: hTERT mRNA was detected by in situ hybridization in 146 samples from patients with NSCLC. The signal intensity of hTERT mRNA expression was evaluated by two independent observers. The expression level was defined subjectively as strong, moderate, or weak.
RESULTS: hTERT mRNA was detected mainly in the cytoplasm of tumor cells. It was detected in the cytoplasm of 100% of samples from patients with NSCLC but was not detected in normal lung tissue, except in activated lymphocytes. There was a significant correlation between hTERT mRNA expression and pathologic tumor status, pathologic disease stage (pStage), and Ki-67 labeling index. There was no significant correlation between hTERT mRNA expression and age, gender, pathologic lymph node status (pN), histology, or tumor differentiation. The 5-year survival rates for patients with strong and moderate hTERT mRNA expression levels were 46.9% and 77.9%, respectively; the difference was statistically significant (P = 0.0001). A multivariate analysis of survival using a stepwise procedure revealed that hTERT mRNA expression, pN status, pStage, and age were statistically significant prognostic factors (P = 0.0029, P = 0.0012, P = 0.0237, and P = 0.0496, respectively).
CONCLUSIONS: The findings suggested that hTERT mRNA expression may be useful for the diagnosis of NSCLC and also may be an independent prognostic factor for patients with NSCLC. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12942569     DOI: 10.1002/cncr.11611

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

Review 1.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

2.  The associations of TERT-CLPTM1L variants and TERT mRNA expression with the prognosis of early stage non-small cell lung cancer.

Authors:  Z Chen; J Wang; Y Bai; S Wang; X Yin; J Xiang; X Li; M He; X Zhang; T Wu; P Xu; H Guo
Journal:  Cancer Gene Ther       Date:  2016-12-16       Impact factor: 5.987

3.  Value of endoscopic methylene blue and Lugol's iodine double staining and detection of GST-Pi and telomerase in the early diagnosis of esophageal carcinoma.

Authors:  Xuan Zhu; Shuang-Hong Zhang; Kun-He Zhang; Bi-Ming Li; Jiang Chen
Journal:  World J Gastroenterol       Date:  2005-10-21       Impact factor: 5.742

4.  In vitro activation of hTERT-specific T cell responses in lung cancer patients following chemotherapy.

Authors:  Benedikt Gahn; Matthias Staudinger; Katrin Woester; Dominique Wellnitz; Sebastian Boettcher; Martin Gramatzki; Michael Kneba
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

5.  A novel biomarker TERTmRNA is applicable for early detection of hepatoma.

Authors:  Norimasa Miura; Yukio Osaki; Miki Nagashima; Michimori Kohno; Kensho Yorozu; Kohei Shomori; Takamasa Kanbe; Kenji Oyama; Yukihiro Kishimoto; Shigeo Maruyama; Eijiro Noma; Yutaka Horie; Masatoshi Kudo; Seigo Sakaguchi; Yasuaki Hirooka; Hisao Ito; Hironaka Kawasaki; Junichi Hasegawa; Goshi Shiota
Journal:  BMC Gastroenterol       Date:  2010-05-18       Impact factor: 3.067

6.  Molecular profiling of single circulating tumor cells from lung cancer patients.

Authors:  Seung-Min Park; Dawson J Wong; Chin Chun Ooi; David M Kurtz; Ophir Vermesh; Amin Aalipour; Susie Suh; Kelsey L Pian; Jacob J Chabon; Sang Hun Lee; Mehran Jamali; Carmen Say; Justin N Carter; Luke P Lee; Ware G Kuschner; Erich J Schwartz; Joseph B Shrager; Joel W Neal; Heather A Wakelee; Maximilian Diehn; Viswam S Nair; Shan X Wang; Sanjiv S Gambhir
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-12       Impact factor: 11.205

7.  Serum messenger RNA as a biomarker and its clinical usefulness in malignancies.

Authors:  Norimasa Miura; Junichi Hasegawa; Goshi Shiota
Journal:  Clin Med Oncol       Date:  2008-09-22

8.  Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer.

Authors:  C-Q Zhu; J-C Cutz; N Liu; D Lau; F A Shepherd; J A Squire; M-S Tsao
Journal:  Br J Cancer       Date:  2006-05-22       Impact factor: 7.640

Review 9.  Vaccine therapy in non-small-cell lung cancer.

Authors:  Carol Albright; Jennifer Garst
Journal:  Curr Oncol Rep       Date:  2007-07       Impact factor: 5.945

Review 10.  Genetic alteration and gene expression modulation during cancer progression.

Authors:  Cathie Garnis; Timon P H Buys; Wan L Lam
Journal:  Mol Cancer       Date:  2004-03-22       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.